A baby believed to be the first person to receive a combination heart transplant and allogeneic processed thymus tissue implantation appears to be gaining the immune cells necessary to reduce or eliminate the need for prolonged use of toxic anti-rejection drugs. The two procedures performed at Duke University Hospital last summer under an expanded access application that was cleared by the FDA represent a milestone in heart transplantation.